Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations

Abstract

The area of pharmacogenetics (PGt) is evolving rapidly. However, ongoing efforts in this field are not aligned with the requirements for the inclusion of clinically relevant findings into the label, especially with reference to paediatric indications. Clinical research in children poses unique issues from a practical and technical perspective, but many challenges can be overcome by applying advanced study design and data analysis methods. When investigating the role of PGt factors on treatment effect, all features that influence drug response must be taken into account. Yet, PGt often has a privileged status in research protocols, with PGt factors evaluated independently from other determinants of response, instead of being regarded as other demographic or clinical covariates (e.g., age, renal function). At present, guidelines to incorporate PGt findings into label statements are lacking in part because this is a new and incompletely understood area. This situation is no longer acceptable. To achieve the potential that PGt can offer to drug development and ultimately to drug prescription, academia, industry and regulatory agencies need to pool resources on the revision of study design and data analysis requisites, bringing in model-based methodologies to enable accurate interpretation of results and provide appropriate labelling recommendations.

Keywords::

• drug labelling
• paediatric clinical trial
• pharmacogenetics
• pharmacodynamic
• pharmacokinetic
• polymorphism
• regulatory approval

Acknowledgements

This publication is the result of concerted efforts by Taskforce in Europe for Drug Development in the Young (TEDDY) Network of Excellence, a project under the auspices of the European Union's Sixth Framework Programme.